Similar articles

• Application of antisense oligonucleotides for gene functionalization and target validation.

  Bennett CF, Cowsert LM. Bennett CF, et al. Curr Opin Mol Ther. 1999 Jun;1(3):359-71. Curr Opin Mol Ther. 1999. PMID: 11713801 Review.
• Triple helix formation and the antigene strategy for sequence-specific control of gene expression.

  Praseuth D, Guieysse AL, Hélène C. Praseuth D, et al. Biochim Biophys Acta. 1999 Dec 10;1489(1):181-206. doi: 10.1016/s0167-4781(99)00149-9. Biochim Biophys Acta. 1999. PMID: 10807007 Review.
• A potent inhibitor of prothrombin gene expression as a result of standardized target site selection and design of antisense oligonucleotides.

  Böhl M, Schwenzer B. Böhl M, et al. Oligonucleotides. 2005 Fall;15(3):172-82. doi: 10.1089/oli.2005.15.172. Oligonucleotides. 2005. PMID: 16201905
• Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.

  Dean NM, McKay R, Miraglia L, Geiger T, Müller M, Fabbro D, Bennett CF. Dean NM, et al. Biochem Soc Trans. 1996 Aug;24(3):623-9. doi: 10.1042/bst0240623. Biochem Soc Trans. 1996. PMID: 8878816 Review. No abstract available.
• Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.

  Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Müller M, Nicklin P. Altmann KH, et al. Biochem Soc Trans. 1996 Aug;24(3):630-7. doi: 10.1042/bst0240630. Biochem Soc Trans. 1996. PMID: 8878817 Review. No abstract available.